Header Logo

Connection

Douglas Golenbock to Cell Line

This is a "connection" page, showing publications Douglas Golenbock has written about Cell Line.
Connection Strength

1.512
  1. Andrade WA, Agarwal S, Mo S, Shaffer SA, Dillard JP, Schmidt T, Hornung V, Fitzgerald KA, Kurt-Jones EA, Golenbock DT. Type I Interferon Induction by Neisseria gonorrhoeae: Dual Requirement of Cyclic GMP-AMP Synthase and Toll-like Receptor 4. Cell Rep. 2016 06 14; 15(11):2438-48.
    View in: PubMed
    Score: 0.095
  2. Meng J, Drolet JR, Monks BG, Golenbock DT. MD-2 residues tyrosine 42, arginine 69, aspartic acid 122, and leucine 125 provide species specificity for lipid IVA. J Biol Chem. 2010 Sep 03; 285(36):27935-43.
    View in: PubMed
    Score: 0.063
  3. Nagpal K, Plantinga TS, Wong J, Monks BG, Gay NJ, Netea MG, Fitzgerald KA, Golenbock DT. A TIR domain variant of MyD88 adapter-like (Mal)/TIRAP results in loss of MyD88 binding and reduced TLR2/TLR4 signaling. J Biol Chem. 2009 Sep 18; 284(38):25742-8.
    View in: PubMed
    Score: 0.059
  4. Latz E, Verma A, Visintin A, Gong M, Sirois CM, Klein DC, Monks BG, McKnight CJ, Lamphier MS, Duprex WP, Espevik T, Golenbock DT. Ligand-induced conformational changes allosterically activate Toll-like receptor 9. Nat Immunol. 2007 Jul; 8(7):772-9.
    View in: PubMed
    Score: 0.051
  5. Visintin A, Halmen KA, Latz E, Monks BG, Golenbock DT. Pharmacological inhibition of endotoxin responses is achieved by targeting the TLR4 coreceptor, MD-2. J Immunol. 2005 Nov 15; 175(10):6465-72.
    View in: PubMed
    Score: 0.046
  6. Henneke P, Morath S, Uematsu S, Weichert S, Pfitzenmaier M, Takeuchi O, M?ller A, Poyart C, Akira S, Berner R, Teti G, Geyer A, Hartung T, Trieu-Cuot P, Kasper DL, Golenbock DT. Role of lipoteichoic acid in the phagocyte response to group B streptococcus. J Immunol. 2005 May 15; 174(10):6449-55.
    View in: PubMed
    Score: 0.044
  7. Schoenemeyer A, Barnes BJ, Mancl ME, Latz E, Goutagny N, Pitha PM, Fitzgerald KA, Golenbock DT. The interferon regulatory factor, IRF5, is a central mediator of toll-like receptor 7 signaling. J Biol Chem. 2005 Apr 29; 280(17):17005-12.
    View in: PubMed
    Score: 0.043
  8. Latz E, Schoenemeyer A, Visintin A, Fitzgerald KA, Monks BG, Knetter CF, Lien E, Nilsen NJ, Espevik T, Golenbock DT. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol. 2004 Feb; 5(2):190-8.
    View in: PubMed
    Score: 0.040
  9. Fitzgerald KA, Rowe DC, Barnes BJ, Caffrey DR, Visintin A, Latz E, Monks B, Pitha PM, Golenbock DT. LPS-TLR4 signaling to IRF-3/7 and NF-kappaB involves the toll adapters TRAM and TRIF. J Exp Med. 2003 Oct 06; 198(7):1043-55.
    View in: PubMed
    Score: 0.039
  10. Visintin A, Latz E, Monks BG, Espevik T, Golenbock DT. Lysines 128 and 132 enable lipopolysaccharide binding to MD-2, leading to Toll-like receptor-4 aggregation and signal transduction. J Biol Chem. 2003 Nov 28; 278(48):48313-20.
    View in: PubMed
    Score: 0.039
  11. Malley R, Henneke P, Morse SC, Cieslewicz MJ, Lipsitch M, Thompson CM, Kurt-Jones E, Paton JC, Wessels MR, Golenbock DT. Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc Natl Acad Sci U S A. 2003 Feb 18; 100(4):1966-71.
    View in: PubMed
    Score: 0.038
  12. Latz E, Visintin A, Lien E, Fitzgerald KA, Espevik T, Golenbock DT. The LPS receptor generates inflammatory signals from the cell surface. J Endotoxin Res. 2003; 9(6):375-80.
    View in: PubMed
    Score: 0.037
  13. Schromm AB, Lien E, Henneke P, Chow JC, Yoshimura A, Heine H, Latz E, Monks BG, Schwartz DA, Miyake K, Golenbock DT. Molecular genetic analysis of an endotoxin nonresponder mutant cell line: a point mutation in a conserved region of MD-2 abolishes endotoxin-induced signaling. J Exp Med. 2001 Jul 02; 194(1):79-88.
    View in: PubMed
    Score: 0.034
  14. Lien E, Chow JC, Hawkins LD, McGuinness PD, Miyake K, Espevik T, Gusovsky F, Golenbock DT. A novel synthetic acyclic lipid A-like agonist activates cells via the lipopolysaccharide/toll-like receptor 4 signaling pathway. J Biol Chem. 2001 Jan 19; 276(3):1873-80.
    View in: PubMed
    Score: 0.032
  15. Ingalls RR, Monks BG, Savedra R, Christ WJ, Delude RL, Medvedev AE, Espevik T, Golenbock DT. CD11/CD18 and CD14 share a common lipid A signaling pathway. J Immunol. 1998 Nov 15; 161(10):5413-20.
    View in: PubMed
    Score: 0.028
  16. Delude RL, Yoshimura A, Ingalls RR, Golenbock DT. Construction of a lipopolysaccharide reporter cell line and its use in identifying mutants defective in endotoxin, but not TNF-alpha, signal transduction. J Immunol. 1998 Sep 15; 161(6):3001-9.
    View in: PubMed
    Score: 0.028
  17. Tamehiro N, Park MH, Hawxhurst V, Nagpal K, Adams ME, Zannis VI, Golenbock DT, Fitzgerald ML. LXR Agonism Upregulates the Macrophage ABCA1/Syntrophin Protein Complex That Can Bind ApoA-I and Stabilized ABCA1 Protein, but Complex Loss Does Not Inhibit Lipid Efflux. Biochemistry. 2015 Nov 24; 54(46):6931-41.
    View in: PubMed
    Score: 0.023
  18. Yang H, Wang H, Ju Z, Ragab AA, Lundb?ck P, Long W, Valdes-Ferrer SI, He M, Pribis JP, Li J, Lu B, Gero D, Szabo C, Antoine DJ, Harris HE, Golenbock DT, Meng J, Roth J, Chavan SS, Andersson U, Billiar TR, Tracey KJ, Al-Abed Y. MD-2 is required for disulfide HMGB1-dependent TLR4 signaling. J Exp Med. 2015 Jan 12; 212(1):5-14.
    View in: PubMed
    Score: 0.022
  19. Delude RL, Savedra R, Yamamoto S, Golenbock DT. Use of CD14 transfected cells to study LPS-antagonist action. Prog Clin Biol Res. 1995; 392:487-97.
    View in: PubMed
    Score: 0.022
  20. Fagan MA, Liu Y, St?tz P, Vyplel H, Golenbock DT. Acyclic analogue of lipid A stimulates TNF-alpha and arachidonate release via a unique LPS-signaling pathway. J Immunol. 1994 Dec 01; 153(11):5230-8.
    View in: PubMed
    Score: 0.021
  21. De la Fuente M, Franchi L, Araya D, D?az-Jim?nez D, Olivares M, ?lvarez-Lobos M, Golenbock D, Gonz?lez MJ, L?pez-Kostner F, Quera R, N??ez G, Vidal R, Hermoso MA. Escherichia coli isolates from inflammatory bowel diseases patients survive in macrophages and activate NLRP3 inflammasome. Int J Med Microbiol. 2014 May; 304(3-4):384-92.
    View in: PubMed
    Score: 0.020
  22. Golenbock DT, Liu Y, Millham FH, Freeman MW, Zoeller RA. Surface expression of human CD14 in Chinese hamster ovary fibroblasts imparts macrophage-like responsiveness to bacterial endotoxin. J Biol Chem. 1993 Oct 15; 268(29):22055-9.
    View in: PubMed
    Score: 0.020
  23. Lynn WA, Liu Y, Golenbock DT. Neither CD14 nor serum is absolutely necessary for activation of mononuclear phagocytes by bacterial lipopolysaccharide. Infect Immun. 1993 Oct; 61(10):4452-61.
    View in: PubMed
    Score: 0.020
  24. Hafner-Bratkovic I, Bencina M, Fitzgerald KA, Golenbock D, Jerala R. NLRP3 inflammasome activation in macrophage cell lines by prion protein fibrils as the source of IL-1? and neuronal toxicity. Cell Mol Life Sci. 2012 Dec; 69(24):4215-28.
    View in: PubMed
    Score: 0.018
  25. Golenbock DT, Hampton RY, Qureshi N, Takayama K, Raetz CR. Lipid A-like molecules that antagonize the effects of endotoxins on human monocytes. J Biol Chem. 1991 Oct 15; 266(29):19490-8.
    View in: PubMed
    Score: 0.017
  26. Lysakova-Devine T, Keogh B, Harrington B, Nagpal K, Halle A, Golenbock DT, Monie T, Bowie AG. Viral inhibitory peptide of TLR4, a peptide derived from vaccinia protein A46, specifically inhibits TLR4 by directly targeting MyD88 adaptor-like and TRIF-related adaptor molecule. J Immunol. 2010 Oct 01; 185(7):4261-71.
    View in: PubMed
    Score: 0.016
  27. Stewart CR, Stuart LM, Wilkinson K, van Gils JM, Deng J, Halle A, Rayner KJ, Boyer L, Zhong R, Frazier WA, Lacy-Hulbert A, El Khoury J, Golenbock DT, Moore KJ. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol. 2010 Feb; 11(2):155-61.
    View in: PubMed
    Score: 0.015
  28. Santos-Sierra S, Deshmukh SD, Kalnitski J, K?enzi P, Wymann MP, Golenbock DT, Henneke P. Mal connects TLR2 to PI3Kinase activation and phagocyte polarization. EMBO J. 2009 Jul 22; 28(14):2018-27.
    View in: PubMed
    Score: 0.015
  29. Diczfalusy U, Olofsson KE, Carlsson AM, Gong M, Golenbock DT, Rooyackers O, Fl?ring U, Bj?rkbacka H. Marked upregulation of cholesterol 25-hydroxylase expression by lipopolysaccharide. J Lipid Res. 2009 Nov; 50(11):2258-64.
    View in: PubMed
    Score: 0.015
  30. Palsson-McDermott EM, Doyle SL, McGettrick AF, Hardy M, Husebye H, Banahan K, Gong M, Golenbock D, Espevik T, O'Neill LA. TAG, a splice variant of the adaptor TRAM, negatively regulates the adaptor MyD88-independent TLR4 pathway. Nat Immunol. 2009 Jun; 10(6):579-86.
    View in: PubMed
    Score: 0.015
  31. Drage MG, Pecora ND, Hise AG, Febbraio M, Silverstein RL, Golenbock DT, Boom WH, Harding CV. TLR2 and its co-receptors determine responses of macrophages and dendritic cells to lipoproteins of Mycobacterium tuberculosis. Cell Immunol. 2009; 258(1):29-37.
    View in: PubMed
    Score: 0.014
  32. Kenzel S, Santos-Sierra S, Deshmukh SD, Moeller I, Ergin B, Fitzgerald KA, Lien E, Akira S, Golenbock DT, Henneke P. Role of p38 and early growth response factor 1 in the macrophage response to group B streptococcus. Infect Immun. 2009 Jun; 77(6):2474-81.
    View in: PubMed
    Score: 0.014
  33. Rhee KJ, Wu S, Wu X, Huso DL, Karim B, Franco AA, Rabizadeh S, Golub JE, Mathews LE, Shin J, Sartor RB, Golenbock D, Hamad AR, Gan CM, Housseau F, Sears CL. Induction of persistent colitis by a human commensal, enterotoxigenic Bacteroides fragilis, in wild-type C57BL/6 mice. Infect Immun. 2009 Apr; 77(4):1708-18.
    View in: PubMed
    Score: 0.014
  34. Sandanger ?, Ryan L, Bohnhorst J, Iversen AC, Husebye H, Halaas ?, Landr? L, Aukrust P, Fr?land SS, Elson G, Visintin A, ?ktedalen O, Dam?s JK, Sundan A, Golenbock D, Espevik T. IL-10 enhances MD-2 and CD14 expression in monocytes and the proteins are increased and correlated in HIV-infected patients. J Immunol. 2009 Jan 01; 182(1):588-95.
    View in: PubMed
    Score: 0.014
  35. Bartholomeu DC, Ropert C, Melo MB, Parroche P, Junqueira CF, Teixeira SM, Sirois C, Kasperkovitz P, Knetter CF, Lien E, Latz E, Golenbock DT, Gazzinelli RT. Recruitment and endo-lysosomal activation of TLR9 in dendritic cells infected with Trypanosoma cruzi. J Immunol. 2008 Jul 15; 181(2):1333-44.
    View in: PubMed
    Score: 0.014
  36. Knapp S, von Aulock S, Leendertse M, Haslinger I, Draing C, Golenbock DT, van der Poll T. Lipoteichoic acid-induced lung inflammation depends on TLR2 and the concerted action of TLR4 and the platelet-activating factor receptor. J Immunol. 2008 Mar 01; 180(5):3478-84.
    View in: PubMed
    Score: 0.013
  37. Davey M, Liu X, Ukai T, Jain V, Gudino C, Gibson FC, Golenbock D, Visintin A, Genco CA. Bacterial fimbriae stimulate proinflammatory activation in the endothelium through distinct TLRs. J Immunol. 2008 Feb 15; 180(4):2187-95.
    View in: PubMed
    Score: 0.013
  38. Ueno K, Koga T, Kato K, Golenbock DT, Gendler SJ, Kai H, Kim KC. MUC1 mucin is a negative regulator of toll-like receptor signaling. Am J Respir Cell Mol Biol. 2008 Mar; 38(3):263-8.
    View in: PubMed
    Score: 0.013
  39. Nordone SK, Ignacio GA, Su L, Sempowski GD, Golenbock DT, Li L, Dean GA. Failure of TLR4-driven NF-kappa B activation to stimulate virus replication in models of HIV type 1 activation. AIDS Res Hum Retroviruses. 2007 Nov; 23(11):1387-95.
    View in: PubMed
    Score: 0.013
  40. Sweet CR, Conlon J, Golenbock DT, Goguen J, Silverman N. YopJ targets TRAF proteins to inhibit TLR-mediated NF-kappaB, MAPK and IRF3 signal transduction. Cell Microbiol. 2007 Nov; 9(11):2700-15.
    View in: PubMed
    Score: 0.013
  41. Chen CJ, Kono H, Golenbock D, Reed G, Akira S, Rock KL. Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat Med. 2007 Jul; 13(7):851-6.
    View in: PubMed
    Score: 0.013
  42. Hise AG, Daehnel K, Gillette-Ferguson I, Cho E, McGarry HF, Taylor MJ, Golenbock DT, Fitzgerald KA, Kazura JW, Pearlman E. Innate immune responses to endosymbiotic Wolbachia bacteria in Brugia malayi and Onchocerca volvulus are dependent on TLR2, TLR6, MyD88, and Mal, but not TLR4, TRIF, or TRAM. J Immunol. 2007 Jan 15; 178(2):1068-76.
    View in: PubMed
    Score: 0.012
  43. Wang Q, McLoughlin RM, Cobb BA, Charrel-Dennis M, Zaleski KJ, Golenbock D, Tzianabos AO, Kasper DL. A bacterial carbohydrate links innate and adaptive responses through Toll-like receptor 2. J Exp Med. 2006 Dec 25; 203(13):2853-63.
    View in: PubMed
    Score: 0.012
  44. Wang JP, Liu P, Latz E, Golenbock DT, Finberg RW, Libraty DH. Flavivirus activation of plasmacytoid dendritic cells delineates key elements of TLR7 signaling beyond endosomal recognition. J Immunol. 2006 Nov 15; 177(10):7114-21.
    View in: PubMed
    Score: 0.012
  45. Visintin A, Halmen KA, Khan N, Monks BG, Golenbock DT, Lien E. MD-2 expression is not required for cell surface targeting of Toll-like receptor 4 (TLR4). J Leukoc Biol. 2006 Dec; 80(6):1584-92.
    View in: PubMed
    Score: 0.012
  46. Yu M, Wang H, Ding A, Golenbock DT, Latz E, Czura CJ, Fenton MJ, Tracey KJ, Yang H. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock. 2006 Aug; 26(2):174-9.
    View in: PubMed
    Score: 0.012
  47. Cario E, Golenbock DT, Visintin A, R?nzi M, Gerken G, Podolsky DK. Trypsin-sensitive modulation of intestinal epithelial MD-2 as mechanism of lipopolysaccharide tolerance. J Immunol. 2006 Apr 01; 176(7):4258-66.
    View in: PubMed
    Score: 0.012
  48. Kenzel S, Mancuso G, Malley R, Teti G, Golenbock DT, Henneke P. c-Jun kinase is a critical signaling molecule in a neonatal model of group B streptococcal sepsis. J Immunol. 2006 Mar 01; 176(5):3181-8.
    View in: PubMed
    Score: 0.012
  49. Knapp S, Florquin S, Golenbock DT, van der Poll T. Pulmonary lipopolysaccharide (LPS)-binding protein inhibits the LPS-induced lung inflammation in vivo. J Immunol. 2006 Mar 01; 176(5):3189-95.
    View in: PubMed
    Score: 0.012
  50. Massari P, Visintin A, Gunawardana J, Halmen KA, King CA, Golenbock DT, Wetzler LM. Meningococcal porin PorB binds to TLR2 and requires TLR1 for signaling. J Immunol. 2006 Feb 15; 176(4):2373-80.
    View in: PubMed
    Score: 0.012
  51. Kishimoto M, Yoshimura A, Naito M, Okamoto K, Yamamoto K, Golenbock DT, Hara Y, Nakayama K. Gingipains inactivate a cell surface ligand on Porphyromonas gingivalis that induces TLR2-and TLR4-independent signaling. Microbiol Immunol. 2006; 50(4):315-25.
    View in: PubMed
    Score: 0.012
  52. Boon Hinckley M, Reynolds CM, Ribeiro AA, McGrath SC, Cotter RJ, Lauw FN, Golenbock DT, Raetz CR. A Leptospira interrogans enzyme with similarity to yeast Ste14p that methylates the 1-phosphate group of lipid A. J Biol Chem. 2005 Aug 26; 280(34):30214-24.
    View in: PubMed
    Score: 0.011
  53. Divanovic S, Trompette A, Atabani SF, Madan R, Golenbock DT, Visintin A, Finberg RW, Tarakhovsky A, Vogel SN, Belkaid Y, Kurt-Jones EA, Karp CL. Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105. Nat Immunol. 2005 Jun; 6(6):571-8.
    View in: PubMed
    Score: 0.011
  54. Divanovic S, Trompette A, Atabani SF, Madan R, Golenbock DT, Visintin A, Finberg RW, Tarakhovsky A, Vogel SN, Belkaid Y, Kurt-Jones EA, Karp CL. Inhibition of TLR-4/MD-2 signaling by RP105/MD-1. J Endotoxin Res. 2005; 11(6):363-8.
    View in: PubMed
    Score: 0.011
  55. Dolganiuc A, Oak S, Kodys K, Golenbock DT, Finberg RW, Kurt-Jones E, Szabo G. Hepatitis C core and nonstructural 3 proteins trigger toll-like receptor 2-mediated pathways and inflammatory activation. Gastroenterology. 2004 Nov; 127(5):1513-24.
    View in: PubMed
    Score: 0.011
  56. Hasebe A, Yoshimura A, Into T, Kataoka H, Tanaka S, Arakawa S, Ishikura H, Golenbock DT, Sugaya T, Tsuchida N, Kawanami M, Hara Y, Shibata K. Biological activities of Bacteroides forsythus lipoproteins and their possible pathological roles in periodontal disease. Infect Immun. 2004 Mar; 72(3):1318-25.
    View in: PubMed
    Score: 0.010
  57. Okusawa T, Fujita M, Nakamura J, Into T, Yasuda M, Yoshimura A, Hara Y, Hasebe A, Golenbock DT, Morita M, Kuroki Y, Ogawa T, Shibata K. Relationship between structures and biological activities of mycoplasmal diacylated lipopeptides and their recognition by toll-like receptors 2 and 6. Infect Immun. 2004 Mar; 72(3):1657-65.
    View in: PubMed
    Score: 0.010
  58. Latz E, Franko J, Golenbock DT, Schreiber JR. Haemophilus influenzae type b-outer membrane protein complex glycoconjugate vaccine induces cytokine production by engaging human toll-like receptor 2 (TLR2) and requires the presence of TLR2 for optimal immunogenicity. J Immunol. 2004 Feb 15; 172(4):2431-8.
    View in: PubMed
    Score: 0.010
  59. Sandor F, Latz E, Re F, Mandell L, Repik G, Golenbock DT, Espevik T, Kurt-Jones EA, Finberg RW. Importance of extra- and intracellular domains of TLR1 and TLR2 in NFkappa B signaling. J Cell Biol. 2003 Sep 15; 162(6):1099-110.
    View in: PubMed
    Score: 0.010
  60. Huang LY, Aliberti J, Leifer CA, Segal DM, Sher A, Golenbock DT, Golding B. Heat-killed Brucella abortus induces TNF and IL-12p40 by distinct MyD88-dependent pathways: TNF, unlike IL-12p40 secretion, is Toll-like receptor 2 dependent. J Immunol. 2003 Aug 01; 171(3):1441-6.
    View in: PubMed
    Score: 0.010
  61. Sau K, Mambula SS, Latz E, Henneke P, Golenbock DT, Levitz SM. The antifungal drug amphotericin B promotes inflammatory cytokine release by a Toll-like receptor- and CD14-dependent mechanism. J Biol Chem. 2003 Sep 26; 278(39):37561-8.
    View in: PubMed
    Score: 0.010
  62. Compton T, Kurt-Jones EA, Boehme KW, Belko J, Latz E, Golenbock DT, Finberg RW. Human cytomegalovirus activates inflammatory cytokine responses via CD14 and Toll-like receptor 2. J Virol. 2003 Apr; 77(8):4588-96.
    View in: PubMed
    Score: 0.010
  63. van der Kleij D, Latz E, Brouwers JF, Kruize YC, Schmitz M, Kurt-Jones EA, Espevik T, de Jong EC, Kapsenberg ML, Golenbock DT, Tielens AG, Yazdanbakhsh M. A novel host-parasite lipid cross-talk. Schistosomal lyso-phosphatidylserine activates toll-like receptor 2 and affects immune polarization. J Biol Chem. 2002 Dec 13; 277(50):48122-9.
    View in: PubMed
    Score: 0.009
  64. Latz E, Visintin A, Lien E, Fitzgerald KA, Monks BG, Kurt-Jones EA, Golenbock DT, Espevik T. Lipopolysaccharide rapidly traffics to and from the Golgi apparatus with the toll-like receptor 4-MD-2-CD14 complex in a process that is distinct from the initiation of signal transduction. J Biol Chem. 2002 Dec 06; 277(49):47834-43.
    View in: PubMed
    Score: 0.009
  65. Mambula SS, Sau K, Henneke P, Golenbock DT, Levitz SM. Toll-like receptor (TLR) signaling in response to Aspergillus fumigatus. J Biol Chem. 2002 Oct 18; 277(42):39320-6.
    View in: PubMed
    Score: 0.009
  66. Flo TH, Ryan L, Latz E, Takeuchi O, Monks BG, Lien E, Halaas ?, Akira S, Skj?k-Braek G, Golenbock DT, Espevik T. Involvement of toll-like receptor (TLR) 2 and TLR4 in cell activation by mannuronic acid polymers. J Biol Chem. 2002 Sep 20; 277(38):35489-95.
    View in: PubMed
    Score: 0.009
  67. Massari P, Henneke P, Ho Y, Latz E, Golenbock DT, Wetzler LM. Cutting edge: Immune stimulation by neisserial porins is toll-like receptor 2 and MyD88 dependent. J Immunol. 2002 Feb 15; 168(4):1533-7.
    View in: PubMed
    Score: 0.009
  68. Medvedev AE, Henneke P, Schromm A, Lien E, Ingalls R, Fenton MJ, Golenbock DT, Vogel SN. Induction of tolerance to lipopolysaccharide and mycobacterial components in Chinese hamster ovary/CD14 cells is not affected by overexpression of Toll-like receptors 2 or 4. J Immunol. 2001 Aug 15; 167(4):2257-67.
    View in: PubMed
    Score: 0.009
  69. Campos MA, Almeida IC, Takeuchi O, Akira S, Valente EP, Proc?pio DO, Travassos LR, Smith JA, Golenbock DT, Gazzinelli RT. Activation of Toll-like receptor-2 by glycosylphosphatidylinositol anchors from a protozoan parasite. J Immunol. 2001 Jul 01; 167(1):416-23.
    View in: PubMed
    Score: 0.008
  70. Shoham S, Huang C, Chen JM, Golenbock DT, Levitz SM. Toll-like receptor 4 mediates intracellular signaling without TNF-alpha release in response to Cryptococcus neoformans polysaccharide capsule. J Immunol. 2001 Apr 01; 166(7):4620-6.
    View in: PubMed
    Score: 0.008
  71. Means TK, Jones BW, Schromm AB, Shurtleff BA, Smith JA, Keane J, Golenbock DT, Vogel SN, Fenton MJ. Differential effects of a Toll-like receptor antagonist on Mycobacterium tuberculosis-induced macrophage responses. J Immunol. 2001 Mar 15; 166(6):4074-82.
    View in: PubMed
    Score: 0.008
  72. Moore KJ, Andersson LP, Ingalls RR, Monks BG, Li R, Arnaout MA, Golenbock DT, Freeman MW. Divergent response to LPS and bacteria in CD14-deficient murine macrophages. J Immunol. 2000 Oct 15; 165(8):4272-80.
    View in: PubMed
    Score: 0.008
  73. Means TK, Lien E, Yoshimura A, Wang S, Golenbock DT, Fenton MJ. The CD14 ligands lipoarabinomannan and lipopolysaccharide differ in their requirement for Toll-like receptors. J Immunol. 1999 Dec 15; 163(12):6748-55.
    View in: PubMed
    Score: 0.008
  74. Means TK, Wang S, Lien E, Yoshimura A, Golenbock DT, Fenton MJ. Human toll-like receptors mediate cellular activation by Mycobacterium tuberculosis. J Immunol. 1999 Oct 01; 163(7):3920-7.
    View in: PubMed
    Score: 0.007
  75. Bhat N, Perera PY, Carboni JM, Blanco J, Golenbock DT, Mayadas TN, Vogel SN. Use of a photoactivatable taxol analogue to identify unique cellular targets in murine macrophages: identification of murine CD18 as a major taxol-binding protein and a role for Mac-1 in taxol-induced gene expression. J Immunol. 1999 Jun 15; 162(12):7335-42.
    View in: PubMed
    Score: 0.007
  76. Kalayoglu MV, Miranpuri GS, Golenbock DT, Byrne GI. Characterization of low-density lipoprotein uptake by murine macrophages exposed to Chlamydia pneumoniae. Microbes Infect. 1999 May; 1(6):409-18.
    View in: PubMed
    Score: 0.007
  77. Chow JC, Young DW, Golenbock DT, Christ WJ, Gusovsky F. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem. 1999 Apr 16; 274(16):10689-92.
    View in: PubMed
    Score: 0.007
  78. Solomon KR, Kurt-Jones EA, Saladino RA, Stack AM, Dunn IF, Ferretti M, Golenbock D, Fleisher GR, Finberg RW. Heterotrimeric G proteins physically associated with the lipopolysaccharide receptor CD14 modulate both in vivo and in vitro responses to lipopolysaccharide. J Clin Invest. 1998 Dec 01; 102(11):2019-27.
    View in: PubMed
    Score: 0.007
  79. Ryan LK, Golenbock DT, Wu J, Vermeulen MW. Characterization of proinflammatory cytokine production and CD14 expression by murine alveolar macrophage cell lines. In Vitro Cell Dev Biol Anim. 1997 Sep; 33(8):647-53.
    View in: PubMed
    Score: 0.006
  80. Lodie TA, Savedra R, Golenbock DT, Van Beveren CP, Maki RA, Fenton MJ. Stimulation of macrophages by lipopolysaccharide alters the phosphorylation state, conformation, and function of PU.1 via activation of casein kinase II. J Immunol. 1997 Feb 15; 158(4):1848-56.
    View in: PubMed
    Score: 0.006
  81. Lo SK, Golenbock DT, Sass PM, Maskati A, Xu H, Silverstein RL. Engagement of the Lewis X antigen (CD15) results in monocyte activation. Blood. 1997 Jan 01; 89(1):307-14.
    View in: PubMed
    Score: 0.006
  82. Birkland TP, Cornwell RD, Golenbock DT, Proctor RA. Comparative study of lipopolysaccharide-, lipid IVa-, and lipid X-induced tumor necrosis factor production in murine macrophage-like cell lines. Adv Exp Med Biol. 1990; 256:399-402.
    View in: PubMed
    Score: 0.004
  83. Hampton RY, Golenbock DT, Raetz CR. Lipid A binding sites in membranes of macrophage tumor cells. J Biol Chem. 1988 Oct 15; 263(29):14802-7.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.